Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies

References

• Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recommendations Rep. 2022;71(No. RR–3):1–95. doi: 10.15585/mmwr.rr7103a1
   PubMed Web of Science ®Google Scholar
• Li A, Rosenthal ES, Rapoport AB, et al. Opioid use disorder and infectious complications in persons who inject drugs. Int Anesthesiol Clin. 2020;58(2):4–11. doi: 10.1097/AIA.0000000000000276
   PubMed Web of Science ®Google Scholar
• Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 2019;393(10182):1760–1772. doi: 10.1016/S0140-6736(18)33078-2
   PubMed Web of Science ®Google Scholar
• Volkow ND. Medications for opioid use disorder: bridging the gap in care. Lancet. 2018;391(10118):285–287. doi: 10.1016/S0140-6736(17)32893-3
   PubMed Web of Science ®Google Scholar
• CDC. Provisional data shows US drug overdose deaths top 100,000 in 2022. NCHS: Blog Of The National Center For Health Statistics. 2023 May 18. https://blogs.cdc.gov/nchs/2023/05/18/7365/.
   Google Scholar
• Althoff KN, Leifheit KM, Park JN, et al. Opioid-related overdose mortality in the era of fentanyl: monitoring a shifting epidemic by person, place, and time. Drug Alcohol Dependence. 2020;216:108321. doi: 10.1016/j.drugalcdep.2020.108321
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Martinez Garza D, Vining SP, et al. New synthetic opioids: clinical considerations and dangers. Pain Ther. 2023;12(2):399–421. doi: 10.1007/s40122-023-00481-6
   PubMed Web of Science ®Google Scholar
• Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Dependence. 2018;193:14–20. doi: 10.1016/j.drugalcdep.2018.08.029
   PubMed Web of Science ®Google Scholar
• Jones CM, Bekheet F, Park JN, et al. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42(1):154–166. doi: 10.1093/epirev/mxaa011
   PubMed Web of Science ®Google Scholar
• Barbalat G, Reddy G, Franck N. Association of globalization with the burden of opioid use disorders 2019. A country-level analysis using targeted maximum likelihood estimation. Globalization Health. 2023;19(1):76. doi: 10.1186/s12992-023-00980-3
   PubMed Web of Science ®Google Scholar
• Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. doi: 10.1038/s41572-019-0137-5
   PubMed Web of Science ®Google Scholar
• Organization PAH. The burden of drug use disorders in the region of the Americas, 2000-2019. Pan American Health Organization; 2021 [cited 2023 Dec 16]. Available from: https://www.paho.org/en/enlace/burden-drug-use-disorders
   Google Scholar
• Murphy SM. The cost of opioid use disorder and the value of aversion. Drug Alcohol Dependence. 2020;217:108382. doi: 10.1016/j.drugalcdep.2020.108382
   PubMed Web of Science ®Google Scholar
• Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The opioid epidemic: a crisis disproportionately impacting black americans and urban communities. J Racial Ethn Health Disparities. 2023;10(4):2039–2053. doi: 10.1007/s40615-022-01384-6
   PubMed Web of Science ®Google Scholar
• Patrick SW, Barfield WD, Poindexter BB, et al. Neonatal opioid withdrawal syndrome. Pediatrics. 2020;146(5). doi: 10.1542/peds.2020-029074
   Web of Science ®Google Scholar
• Stulac S, Bair-Merritt M, Wachman EM, et al. Children and families of the opioid epidemic: under the radar. Curr Probl Pediatr Adolesc Health Care. 2019;49(8):100637. doi: 10.1016/j.cppeds.2019.07.002
   PubMed Web of Science ®Google Scholar
• Tabatabaeepour N, Morgan JR, Jalali A, et al. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder. J Subst Abuse Treat. 2022;140:108800. doi: 10.1016/j.jsat.2022.108800
   PubMed Web of Science ®Google Scholar
• Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128(1):4–10. doi: 10.1097/AOG.0000000000001446
   PubMed Web of Science ®Google Scholar
• Meinhofer A, Onuoha E, Angleró-Díaz Y, et al. Parental drug use and racial and ethnic disproportionality in the U.S. foster care system. Child Youth Services Rev. 2020;118:105336. doi: 10.1016/j.childyouth.2020.105336
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Sacks DW, Yoo H. The effects of the opioid crisis on employment. Evidence From Labor Market Flows. 2023:1121–12018R2. doi: 10.3368/jhr.1121-12018R2
   Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622–e1920622. doi: 10.1001/jamanetworkopen.2019.20622
   PubMed Web of Science ®Google Scholar
• Jalali A, Ryan DA, Jeng PJ, et al. Health-related quality of life and opioid use disorder pharmacotherapy: a secondary analysis of a clinical trial. Drug Alcohol Dependence. 2020;215:108221. doi: 10.1016/j.drugalcdep.2020.108221
   PubMed Web of Science ®Google Scholar
• Murphy SM, Polsky D. Economic evaluations of opioid use disorder interventions. PharmacoEconomics. 2016;34(9):863–887. doi: 10.1007/s40273-016-0400-5
   PubMed Web of Science ®Google Scholar
• Sharma A, Kelly SM, Mitchell SG, et al. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35. doi: 10.1007/s11920-017-0783-9
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, et al. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. doi: 10.1016/j.jsat.2018.09.001
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Picher CE, Feder KA, et al. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff. 2017;36(12):2046–2053. doi: 10.1377/hlthaff.2017.0890
   PubMed Web of Science ®Google Scholar
• Jalali A, Jeng PJ, Polsky D, et al. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release. J Subst Abuse Treat. 2022;141:108835. doi: 10.1016/j.jsat.2022.108835
   PubMed Web of Science ®Google Scholar
• Lappan SN, Brown AW, Hendricks PS. Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Addiction. 2020;115(2):201–217. doi: 10.1111/add.14793
   PubMed Web of Science ®Google Scholar
• Paschen-Wolff MM, Kidd JD, Paine EA. The state of the research on Opioid Outcomes Among Lesbian, gay, bisexual, transgender, queer, and other sexuality- and gender-diverse populations: a scoping review. LGBT Health. 2023;10(1):1–17. doi: 10.1089/lgbt.2022.0036
   PubMed Web of Science ®Google Scholar
• Hollander MAG, Chang C-C, Douaihy AB, et al. Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use. Drug Alcohol Dependence. 2021;227:108927. doi: 10.1016/j.drugalcdep.2021.108927
   PubMed Web of Science ®Google Scholar
• Priest KC, King CA, Englander H, et al. Differences in the delivery of medications for opioid use disorder during hospitalization by Racial Categories: a retrospective cohort analysis. Subst Abus. 2022;43(1):1251–1259. doi: 10.1080/08897077.2022.2074601
   PubMed Web of Science ®Google Scholar
• Barnett ML, Meara E, Lewinson T, et al. Racial inequality in receipt of medications for opioid use disorder. N Engl J Med. 2023;388(19):1779–1789. doi: 10.1056/NEJMsa2212412
   PubMed Web of Science ®Google Scholar
• Kunins HV. Structural racism and the opioid overdose epidemic: the need for antiracist public health practice. J Public Health Manag Pract. 2020;26(3):201–205. doi: 10.1097/PHH.0000000000001168
   PubMed Web of Science ®Google Scholar
• Farahmand P, Arshed A, Bradley MV. Systemic racism and substance use disorders. Psychiatr Ann. 2020;50(11):494–498. doi: 10.3928/00485713-20201008-01
   Web of Science ®Google Scholar
• Parlier-Ahmad AB, Pugh M, Martin CE. Treatment outcomes among black adults receiving medication for opioid use disorder. J Racial Ethn Health Disparities. 2022;9(4):1557–1567. doi: 10.1007/s40615-021-01095-4
   PubMed Web of Science ®Google Scholar
• Hoffman KA, Baker R, Kunkel LE, et al. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Serv Res. 2019;19(1):862. doi: 10.1186/s12913-019-4721-x
   PubMed Web of Science ®Google Scholar
• Frew PM, Saint-Victor DS, Isaacs MB, et al. Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices. Clin Infect Dis. 2014;59(Suppl 7):S400–7. doi: 10.1093/cid/ciu726
   PubMedGoogle Scholar
• Maclean JC, McClellan C, Pesko MF, et al. Medicaid reimbursement rates for primary care services and behavioral health outcomes. Health Econ. 2023;32(4):873–909. doi: 10.1002/hec.4646
   PubMed Web of Science ®Google Scholar
• Håkansson A, Berglund M. Risk factors for criminal recidivism–a prospective follow-up study in prisoners with substance abuse. BMC Psychiatry. 2012;12(1):1. doi: 10.1186/1471-244X-12-111
   PubMedGoogle Scholar
• Cronin CE, Franz B, Skinner D, et al. Hospitals and substance use disorder services in the time of the opioid epidemic. Health Serv Res. 2019;54(2):399–406. doi: 10.1111/1475-6773.13116
   PubMed Web of Science ®Google Scholar
• Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information—report of the ISPOR task force on use of Pharmacoeconomic/health economic information in health-care decision making. Value Health. 2003;6(4):407–416. doi: 10.1046/j.1524-4733.2003.64245.x
   PubMed Web of Science ®Google Scholar
• Hoch JS. Improving the efficiency of cost-effectiveness analysis to inform policy decisions in the real world: lessons from the pharmacoeconomics research unit at cancer care ontario. In: Zaric G, editor. Operations Research and Health care policy. New York (NY): Springer New York; 2013. p. 399–416.
   Google Scholar
• van Velden ME, Severens JL, Novak A, et al. Economic evaluations of healthcare programmes and decision making. PharmacoEconomics. 2005;23(11):1075–1082. doi: 10.2165/00019053-200523110-00002
   PubMed Web of Science ®Google Scholar
• McGregor M, Caro JJ. QALYs. PharmacoEconomics. 2006;24(10):947–952. doi: 10.2165/00019053-200624100-00002
   PubMed Web of Science ®Google Scholar
• Lyles A. Decision-makers′ use of pharmacoeconomics: what does the research tell us? Expert Rev Pharmacoecon Outcomes Res. 2001;1(2):133–144. doi: 10.1586/14737167.1.2.133
   PubMedGoogle Scholar
• Yagudina RI, Kulikov AU, Serpik VG, et al. Concept of combining cost-effectiveness analysis and budget impact analysis in health care decision-making. Value Health Reg Issues. 2017 Sep 01;13:61–66. doi: 10.1016/j.vhri.2017.07.006
   PubMedGoogle Scholar
• DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. PharmacoEconomics. 2001;19(7):753–766. doi: 10.2165/00019053-200119070-00004
   PubMed Web of Science ®Google Scholar
• Shih Y-C. Bayesian approach in pharmacoeconomics: relevance to decision-makers. Expert rev pharmacoecon outcomes res. 2003;3(3):237–250. doi: 10.1586/14737167.3.3.237
   PubMedGoogle Scholar
• Hartz S, John J. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review. Int J Technol Assess Health Care. 2008;24(4):465–472. doi: 10.1017/S0266462308080616
   PubMed Web of Science ®Google Scholar
• Zaidi STR, Z-U-D B. Applying pharmacoeconomics in community and hospital pharmacy research. In: Z-U-D B, editor. Pharmacy practice research methods. Cham: Springer International Publishing; 2015. p. 157–173.
   Google Scholar
• Murphy SM, Jeng PJ, Poole SA, et al. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Practice. 2020;15(1):15. doi: 10.1186/s13722-020-00188-5
   PubMed Web of Science ®Google Scholar
• Doran CM. Economic evaluation of interventions to treat opiate dependence. PharmacoEconomics. 2008;26(5):371–393. doi: 10.2165/00019053-200826050-00003
   PubMed Web of Science ®Google Scholar
• Onuoha EN, Leff JA, Schackman BR, et al. Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value Health. 2021;24(7):1068–1083. doi: 10.1016/j.jval.2020.12.023
   PubMed Web of Science ®Google Scholar
• Jalali A, Ryan DA, McCollister KE, et al. Economic evaluation in the national drug abuse treatment clinical trials network: past, present, and future. J Subst Abuse Treat. 2020;112:18–27. doi: 10.1016/j.jsat.2020.02.002
   Web of Science ®Google Scholar
• Murphy SM, Laiteerapong N, Pho MT, et al. Health economic analyses of the justice community opioid innovation network (JCOIN). J Subst Abuse Treat. 2021;128:108262. doi: 10.1016/j.jsat.2020.108262
   PubMed Web of Science ®Google Scholar
• Dunlap LJ, Kuklinski MR, Cowell A, et al. Economic evaluation design within the HEAL prevention cooperative. Prevent Sci. 2023;24(1):50–60. doi: 10.1007/s11121-022-01400-5
   PubMed Web of Science ®Google Scholar
• Aldridge AP, Barbosa C, Barocas JA, et al. Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing communities study. Drug Alcohol Dependence. 2020;217:108336. doi: 10.1016/j.drugalcdep.2020.108336
   PubMed Web of Science ®Google Scholar
• Listl S, Wensing M. Economic evaluation in health services research. In: Wensing M Ullrich C, editors. Foundations of Health Services Research: principles, methods, and topics. Cham: Springer International Publishing; 2023. p. 187–198.
   Google Scholar
• Tonin FS, Leonart LP, Casas C. Pharmacoeconomic analysis methods. In: Babar Z-U-D, editor. Encyclopedia of evidence in pharmaceutical public health and health services research in pharmacy. Cham: Springer International Publishing; 2023. p. 1057–1074.
   Google Scholar
• Crotty K, Freedman KI, Kampman KM. Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. J Addict Med. 2020;14(2):99–112. doi: 10.1097/ADM.0000000000000635
   PubMed Web of Science ®Google Scholar
• Leyrer-Jackson JM, Acuña AM, Olive MF. Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update. Expert Opin Pharmacother. 2022;23(16):1819–1830. doi: 10.1080/14656566.2022.2140039
   PubMed Web of Science ®Google Scholar
• Bruneau J, Ahamad K, Goyer M-È, et al. Management of opioid use disorders: a national clinical practice guideline. CanMed Assoc J. 2018;190(9):E247–E257. doi: 10.1503/cmaj.170958
   PubMed Web of Science ®Google Scholar
• Ayanga D, Shorter D, Kosten TR. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother. 2016;17(17):2307–2318. doi: 10.1080/14656566.2016.1244529
   PubMed Web of Science ®Google Scholar
• Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333–340. doi: 10.1080/00952990.2019.1605372
   PubMed Web of Science ®Google Scholar
• Mutter R, Spencer D, McPheeters T. Factors Associated with Initial Treatment Choice, engagement, and discontinuation for patients with opioid use disorder. Psychiatric Serv. 2022;73(6):604–612. doi: 10.1176/appi.ps.202100239
   PubMed Web of Science ®Google Scholar
• Bolívar HA, Klemperer EM, Coleman SRM, et al. Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(10):1092–1102. doi: 10.1001/jamapsychiatry.2021.1969
   PubMed Web of Science ®Google Scholar
• Maricich YA, Bickel WK, Marsch LA, et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2021;37(2):167–173. doi: 10.1080/03007995.2020.1846022
   PubMed Web of Science ®Google Scholar
• Wang W, Gellings Lowe N, Jalali A, et al. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ. 2021;24(1):61–68. doi: 10.1080/13696998.2020.1858581
   PubMed Web of Science ®Google Scholar
• Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–993. doi: 10.1001/jamapsychiatry.2021.0976
   PubMed Web of Science ®Google Scholar
• Calcaterra SL, Bach P, Chadi A, et al. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–1042. doi: 10.1007/s11606-018-4801-3
   PubMed Web of Science ®Google Scholar
• Jehan S, Zahnd WE, Wooten NR, et al. Geographic variation in availability of opioid treatment programs across U.S. communities. J Addict Dis. 2023;42(2):1–11. doi: 10.1080/10550887.2023.2165869
   Google Scholar
• Kleinman RA. Comparison of Driving Times to Opioid Treatment Programs and pharmacies in the US. JAMA Psychiatry. 2020;77(11):1163–1171. doi: 10.1001/jamapsychiatry.2020.1624
   PubMed Web of Science ®Google Scholar
• Olsen Y, Mason A. Bringing primary care to opioid treatment programs. In: Wakeman S Rich J, editors. Treating opioid use disorder in General medical settings. Cham: Springer International Publishing; 2021. p. 173–188.
   Google Scholar
• McCarty D, Bougatsos C, Chan B, et al. Office-based methadone treatment for opioid use disorder and pharmacy dispensing: a scoping review. Am J Psychiatry. 2021;178(9):804–817. doi: 10.1176/appi.ajp.2021.20101548
   PubMed Web of Science ®Google Scholar
• Qian J, Khatiwada AP, Xue X. Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population? Am J Addict. 2023;33(3):335–338. doi: 10.1111/ajad.13505
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Fanucchi LC. Long-acting buprenorphine injectables: opportunity to improve opioid use disorder treatment among rural populations. Preventive med. 2021;152:106756. doi: 10.1016/j.ypmed.2021.106756
   PubMed Web of Science ®Google Scholar
• Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103. doi: 10.1097/ADM.0000000000000457
   PubMed Web of Science ®Google Scholar
• Elkader A, Sproule B. Buprenorphine. Clin Pharmacokinet. 2005;44(7):661–680. doi: 10.2165/00003088-200544070-00001
   PubMed Web of Science ®Google Scholar
• Cohen SM, Weimer MB, Levander XA, et al. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med. 2022;16(4):399–406. doi: 10.1097/ADM.0000000000000945
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Z-E-H L, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197–1205. doi: 10.1001/jamapsychiatry.2017.3206
   PubMed Web of Science ®Google Scholar
• Farabee D, Condon T, Hallgren KA, et al. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder. J Subst Abuse Treat. 2020;117:108076. doi: 10.1016/j.jsat.2020.108076
   PubMed Web of Science ®Google Scholar
• Banta-Green CJ, Floyd AS, Vick K, et al. Opioid use disorder treatment decision making and care navigation upon release from prison: a feasibility study. Subst Abuse Rehabil. 2019;10:57–67. doi: 10.2147/SAR.S192045
   PubMed Web of Science ®Google Scholar
• McNeely J, Troxel AB, Kunins HV, et al. Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in hospitals (CATCH) model for engaging patients in opioid use disorder treatment. Addict Sci Clin Practice. 2019;14(1):5. doi: 10.1186/s13722-019-0135-7
   PubMedGoogle Scholar
• Morgan JR, Schackman BR, Weinstein ZM, et al. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Dependence. 2019;200:34–39. doi: 10.1016/j.drugalcdep.2019.02.031
   PubMed Web of Science ®Google Scholar
• Sibai M, Mishlen K, Nunes EV, et al. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. Am J Drug Alcohol Abuse. 2020;46(3):289–296. doi: 10.1080/00952990.2019.1700265
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129–137. doi: 10.1176/appi.ajp.2018.17070732
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Basaraba C, Pavlicova M, et al. Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder. Am J Drug Alcohol Abuse. 2023;49(5):618–629. doi: 10.1080/00952990.2023.2241981
   PubMed Web of Science ®Google Scholar
• Greiner MG, Shulman M, Opara O, et al. Surmounting withdrawal to initiate fast treatment with naltrexone (SWIFT): a stepped wedge hybrid type 1 effectiveness-implementation study. Contemp Clin Trials. 2023;128:107148. doi: 10.1016/j.cct.2023.107148
   PubMed Web of Science ®Google Scholar
• Bardwell G, Wood E, Brar R. Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Substance abuse treatment. Prevention, And Policy. 2019;14(1):50. doi: 10.1186/s13011-019-0241-2
   Google Scholar
• Brothers TD, Fraser J, MacAdam E, et al. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Drug Alcohol Rev. 2022;41(2):430–434. doi: 10.1111/dar.13365
   PubMed Web of Science ®Google Scholar
• McNair R, Monaghan M, Montgomery P. Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: a context-focused systematic review. Drug Alcohol Dependence. 2023;247:109869. doi: 10.1016/j.drugalcdep.2023.109869
   PubMedGoogle Scholar
• Melis F, Hesse M, Eide D, et al. Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark. Drug Alcohol Dependence. 2024;254:111051. doi: 10.1016/j.drugalcdep.2023.111051
   PubMed Web of Science ®Google Scholar
• Liebrenz M, Gamma A, Buadze A, et al. Fifteen years of heroin-assisted treatment in a Swiss prison—a retrospective cohort study. Harm Reduct J. 2020;17(1):67. doi: 10.1186/s12954-020-00412-0
   PubMed Web of Science ®Google Scholar
• Frank L, Basch E, Selby JV, et al. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312(15):1513–1514. doi: 10.1001/jama.2014.11100
   PubMed Web of Science ®Google Scholar
• Care TAGSEPo P-C. Person-centered care: a definition and essential elements. J Am Geriatr Soc. 2016;64(1):15–18.
   PubMed Web of Science ®Google Scholar
• Freund DA, Dittus RS. Taxonomy of pharmacoeconomics. PharmacoEconomics. 1992;1(1):30–31. doi: 10.2165/00019053-199201010-00007
   Google Scholar
• Drummond MF, Schulpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes. Fourth ed. Oxford, UK: Oxford University Press; 2015.
   Google Scholar
• Drummond MF. Economic Evaluation of Pharmaceuticals. PharmacoEconomics. 1992;1(1):8–13. doi: 10.2165/00019053-199201010-00004
   PubMedGoogle Scholar
• Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. PharmacoEconomics. 1998;14(1):1–9. doi: 10.2165/00019053-199814010-00001
   PubMed Web of Science ®Google Scholar
• Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies. PharmacoEconomics. 1997;11(2):159–168. doi: 10.2165/00019053-199711020-00005
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195
   PubMed Web of Science ®Google Scholar
• Zoratti MJ, Pickard AS, Stalmeier PFM, et al. Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. Eur J Health Econ. 2021;22(5):723–733. doi: 10.1007/s10198-021-01286-0
   PubMed Web of Science ®Google Scholar
• O’Rourke B, Oortwijn W, Schuller T. The new definition of health technology assessment: a milestone in international collaboration. Int J Technol Assess Health Care. 2020;36(3):187–190. doi: 10.1017/S0266462320000215
   PubMed Web of Science ®Google Scholar
• Rotter JS, Foerster D, Bridges JFP. The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):711–723. doi: 10.1586/erp.12.73
   PubMed Web of Science ®Google Scholar
• Jalali A, Tamimi RM, McPherson SM, et al. Econometric issues in prospective economic evaluations alongside clinical trials: combining the nonparametric bootstrap with methods that address missing data. Epidemiol Rev. 2022;44(1):67–77. doi: 10.1093/epirev/mxac006
   PubMed Web of Science ®Google Scholar
• Heeg BM, van Hout BA. Assessing uncertainties surrounding combined endpoints for use in economic models. Med Decis Mak. 2014;34(3):300–310. doi: 10.1177/0272989X13517180
   PubMed Web of Science ®Google Scholar
• Willan AR. Statistical analysis of cost–effectiveness data from randomized clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):337–346. doi: 10.1586/14737167.6.3.337
   PubMedGoogle Scholar
• Saxon AJ, Edelman EJ. Introduction to the special series: national drug abuse treatment clinical trials network and the opioid use disorder care continuum—20 years of research informing practice. Addict Sci Clin Practice. 2022;17(1):7. doi: 10.1186/s13722-022-00291-9
   PubMed Web of Science ®Google Scholar
• Ducharme LJ, Wiley TRA, Mulford CF, et al. Engaging the justice system to address the opioid crisis: the justice Community opioid Innovation Network (JCOIN). J Subst Abuse Treat. 2021;128:108307. doi: 10.1016/j.jsat.2021.108307
   PubMed Web of Science ®Google Scholar
• Cance JD, Adams ET, D’Amico EJ, et al. Leveraging the full continuum of care to prevent opioid use disorder. Prevent Sci. 2023;24(1):30–39. doi: 10.1007/s11121-023-01545-x
   PubMed Web of Science ®Google Scholar
• Gopaldas M, Wenzel K, Campbell ANC, et al. Impact of medication-based treatment on health care utilization among individuals with opioid use disorder. Psychiatric Serv. 2023;74(12):1227–1233. doi: 10.1176/appi.ps.20220549
   PubMed Web of Science ®Google Scholar
• Sordo L, Bravo MJ, Barrio G, et al. Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis. Addiction. 2015;110(8):1247–1257. doi: 10.1111/add.12940
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29(9):1101–1110. doi: 10.1002/pds.5083
   PubMed Web of Science ®Google Scholar
• Murphy SM, Jeng PJ, McCollister KE, et al. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. Addiction. 2021;116(12):3444–3453. doi: 10.1111/add.15531
   PubMed Web of Science ®Google Scholar
• Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam’s injection-driven HIV epidemics. Drug Alcohol Dependence. 2012;125(3):260–266. doi: 10.1016/j.drugalcdep.2012.02.021
   PubMed Web of Science ®Google Scholar
• Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2012;24(3):283–290. doi: 10.1080/09540121.2011.608420
   PubMed Web of Science ®Google Scholar
• Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine–naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616–1624. doi: 10.1111/j.1360-0443.2010.03001.x
   PubMed Web of Science ®Google Scholar
• Maas J, Barton G, Maskrey V, et al. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment. Drug Alcohol Dependence. 2013;133(2):494–501. doi: 10.1016/j.drugalcdep.2013.07.018
   PubMed Web of Science ®Google Scholar
• Jackson H, Mandell K, Johnson K, et al. Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence. Subst Abus. 2015;36(2):226–231. doi: 10.1080/08897077.2015.1010031
   PubMed Web of Science ®Google Scholar
• Ruger JP, Chawarski M, Mazlan M, et al. Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia. PLOS ONE. 2012;7(12):e50673. doi: 10.1371/journal.pone.0050673
   PubMed Web of Science ®Google Scholar
• Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CanMed Assoc J. 2012;184(6):E317–E328. doi: 10.1503/cmaj.110669
   PubMed Web of Science ®Google Scholar
• Barrett B, Byford S, Cary M, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203(5):341–349. doi: 10.1192/bjp.bp.112.111583
   PubMed Web of Science ®Google Scholar
• Choi SA, Yan CH, Gastala NM, et al. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective. J Substance Use Addiction Treatment. 2024;160:209237. doi: 10.1016/j.josat.2023.209237
   PubMedGoogle Scholar
• Dunlop AJ, Brown AL, Oldmeadow C, et al. Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. Drug Alcohol Dependence. 2017;174:181–191. doi: 10.1016/j.drugalcdep.2017.01.016
   PubMed Web of Science ®Google Scholar
• King JB, Sainski-Nguyen AM, Bellows BK. Office-Based Buprenorphine versus clinic-Based methadone: a cost-effectiveness analysis. J Pain Palliative Care Pharmacother. 2016;30(1):55–65. doi: 10.3109/15360288.2015.1135847
   PubMed Web of Science ®Google Scholar
• Busch SH, Fiellin DA, Chawarski MC, et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction. 2017;112(11):2002–2010. doi: 10.1111/add.13900
   PubMed Web of Science ®Google Scholar
• Murphy SM, McCollister KE, Leff JA, et al. Cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone to prevent opioid relapse. Ann internal med. 2019;170(2):90–98. doi: 10.7326/M18-0227
   PubMed Web of Science ®Google Scholar
• Premkumar A, Grobman WA, Terplan M, et al. Methadone, buprenorphine, or detoxification for management of perinatal opioid use disorder: a cost-effectiveness analysis. Obstet & Gynecol. 2019;134(5):921–931. doi: 10.1097/AOG.0000000000003503
   PubMed Web of Science ®Google Scholar
• Smith L, Mosley J, Johnson J, et al. Probuphine (buprenorphine) subdermal implants for the treatment of opioid-dependent patients. Pharm Ther. 2017;42(8):505–508.
   Google Scholar
• Bansback N, Guh D, Oviedo-Joekes E, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264–1273. doi: 10.1111/add.14171
   PubMed Web of Science ®Google Scholar
• Enns B, Krebs E, Whitehurst DGT, et al. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder. Drug Alcohol Dependence. 2023;247:109893. doi: 10.1016/j.drugalcdep.2023.109893
   PubMed Web of Science ®Google Scholar
• Jawa R, Tin Y, Nall S, et al. Estimated clinical outcomes and cost-effectiveness associated with provision of addiction treatment in US primary care clinics. JAMA Netw Open. 2023;6(4):e237888–e237888. doi: 10.1001/jamanetworkopen.2023.7888
   PubMed Web of Science ®Google Scholar
• van Rooij T, Wilson DM, Marsh S. Personalized medicine policy challenges: measuring clinical utility at point of care. Expert rev pharmacoecon outcomes res. 2012;12(3):289–295. doi: 10.1586/erp.12.15
   PubMed Web of Science ®Google Scholar
• Dewitt B, Feeny D, Fischhoff B, et al. Estimation of a preference-based summary score for the patient-reported outcomes measurement information system: the PROMIS®-preference (PROPr) scoring system. Med Decis Mak. 2018;38(6):683–698. doi: 10.1177/0272989X18776637
   PubMed Web of Science ®Google Scholar
• Joshua Lin K, Jin Y, Gagne J, et al. Longitudinal Data Discontinuity in Electronic Health Records and consequences for medication effectiveness studies. Clinical Pharmacology & Therapeutics. 2022;111(1):243–251. doi: 10.1002/cpt.2400
   PubMed Web of Science ®Google Scholar
• Murphy SM, Laiteerapong N, Pho MT, et al. Health economic analyses of the justice community opioid innovation network (JCOIN). J Substance Use Addiction Treatment. [2021 Jan 5];128:108262. doi: 10.1016/j.jsat.2020.108262
   Google Scholar
• Ridenour TA, Cruden G, Yang Y, et al. Methodological strategies for prospective harmonization of studies: application to 10 distinct outcomes studies of preventive interventions targeting opioid misuse. Prevent Sci. 2023;24(1):16–29. doi: 10.1007/s11121-022-01412-1
   PubMed Web of Science ®Google Scholar
• Wong J. The History of Technology Assessment and Comparative Effectiveness Research for Drugs and Medical Devices and the role of the federal government. Biotechnol Law Rep. [2014 Dec 1];33(6):221–248. doi: 10.1089/blr.2014.9967
   PubMed Web of Science ®Google Scholar
• Darrow JJ, Avorn J, Kesselheim AS. FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA. 2020;323(2):164–176. doi: 10.1001/jama.2019.20288
   PubMed Web of Science ®Google Scholar
• Dopp AR, Kerns SEU, Panattoni L, et al. Translating economic evaluations into financing strategies for implementing evidence-based practices. Implement Sci. 2021;16(1):66. doi: 10.1186/s13012-021-01137-9
   PubMed Web of Science ®Google Scholar
• Hodgkin D, Horgan C, Bart G. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics. Addict Sci Clin Practice. 2021;16(1):45. doi: 10.1186/s13722-021-00253-7
   PubMed Web of Science ®Google Scholar
• Glasgow RE, Harden SM, Gaglio B, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review [mini review]. Front Public Health. 2019;7. doi: 10.3389/fpubh.2019.00064
   Web of Science ®Google Scholar
• Ryan DA, Montoya ID, Koutoujian PJ, et al. Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities. J Substance Use Addiction Treatment. 2023;146:208943. doi: 10.1016/j.josat.2022.208943
   PubMedGoogle Scholar
• Jones CM, Shoff C, Hodges K, et al. Receipt of Telehealth Services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79(10):981–992. doi: 10.1001/jamapsychiatry.2022.2284
   PubMed Web of Science ®Google Scholar
• Jones CM, Han B, Baldwin GT, et al. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488–e2327488. doi: 10.1001/jamanetworkopen.2023.27488
   PubMed Web of Science ®Google Scholar
• Tofighi B, Abrantes A, Stein MD. The role of technology-based interventions for substance use disorders in primary care: a review of the literature. Med Clin North Am. 2018;102(4):715–731. doi: 10.1016/j.mcna.2018.02.011
   PubMed Web of Science ®Google Scholar
• Samuels EA, Khatri UG, Snyder H, et al. Buprenorphine telehealth treatment initiation and follow-up during COVID-19. J Gen Intern Med. 2022;37(5):1331–1333. doi: 10.1007/s11606-021-07249-8
   PubMed Web of Science ®Google Scholar
• Tofighi B, Grazioli F, Bereket S, et al. Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: a feasibility study. Am J Addict. 2017;26(6):581–586. doi: 10.1111/ajad.12557
   PubMed Web of Science ®Google Scholar
• Polsky D, Sen AP, Arsenault S. Innovative payment to scale up access to medications for opioid use disorder. Am J Manag Care. 2020;26(7):286–287.
   PubMed Web of Science ®Google Scholar
• Miller EA, DeVeaugh-Geiss AM, Chilcoat HD. Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids. Drug Alcohol Depend. 2024;10:100220. doi: 10.1016/j.dadr.2024.100220
   Web of Science ®Google Scholar
• Archambault L, Bertrand K, Martel MO, et al. The current state of knowledge on care for co-occurring chronic pain and opioid use disorder: a scoping review. J Clin Nurs. 2024;1–21. doi: 10.1111/jocn.17139
   Web of Science ®Google Scholar
• Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder – decades of effectiveness but still miles away in the US. JAMA Psychiatry. 2020;77(11):1105–1106. doi: 10.1001/jamapsychiatry.2020.1511
   PubMed Web of Science ®Google Scholar
• McDougall JA, Furnback WE, Wang BCM, et al. Understanding the Global Measurement of Willingness to pay in health. J Mark Access Health Policy. 2020;8(1):1717030. doi: 10.1080/20016689.2020.1717030
   PubMedGoogle Scholar
• Sharma D, Aggarwal AK, Downey LE, et al. National Healthcare Economic Evaluation Guidelines: a cross-country comparison. Pharmacoecon Open. 2021;5(3):349–364. doi: 10.1007/s41669-020-00250-7
   PubMed Web of Science ®Google Scholar